On Tuesday, iNCOVACC (BBV154), an intranasal vaccine developed by Bharat Biotech International Limited (BBIL), was approved by the Drugs Controller General of India (DCGI) under Restricted Use in Emergency Situations for ages 18 and above. The world′s first intranasal COVID-19 vaccine is about to hit the market, nearly three years after the novel coronavirus started spreading among nations. Medical experts and healthcare professionals are hailing the second-generation vaccine as a revolutionary development against the COVID-19 virus.

Dr. Krishna Ella, Chairman and Managing Director at Bharat Biotech, while commenting on the achievement, said, "We are proud to announce the approval of iNCOVACC, a global game changer in intranasal vaccine technology and delivery systems. Despite the lack of demand for COVID-19 vaccines, we continued product development in intra-nasal vaccines to ensure that we are well prepared with platform technologies for future infectious diseases. "

The new iNCOVACC intranasal vaccine is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. In a press release, the vaccine makers explained that the vaccine candidate was evaluated in phase I, II, and III clinical trials with successful results. In the clinical trial, the vaccine was used as the heterologous booster dose for subjects who had previously received two doses of the commonly administered COVID vaccine in India. 

(Source: https://www.outlookindia.com/national/bharat-biotech-s-nasal-covid-vaccine-first-in-world-to-get-emergency-use-nod-all-you-need-to-know-news-221524 )